Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications.
about
Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisalA systematic review of type 2 diabetes mellitus and hypertension in imaging studies of cognitive aging: time to establish new normsTherapeutic targets of brain insulin resistance in sporadic Alzheimer's diseaseBrain insulin resistance and deficiency as therapeutic targets in Alzheimer's diseaseA humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic miceCeramide-mediated insulin resistance and impairment of cognitive-motor functionsNitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.Current and future uses of neuroimaging for cognitively impaired patients.Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration.Treadmill exercise alleviates impairment of spatial learning ability through enhancing cell proliferation in the streptozotocin-induced Alzheimer's disease rats.Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activationIncreased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitisAlzheimer's disease is type 3 diabetes-evidence reviewed.Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseasesType 3 diabetes is sporadic Alzheimer׳s disease: mini-review.Insulin metabolism and the risk of Alzheimer disease: the Rotterdam StudyInsulin signaling in sporadic Alzheimer's diseaseTranscranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's diseaseChemical Complexity and the Genetics of Aging.Aging-related gene expression in hippocampus proper compared with dentate gyrus is selectively associated with metabolic syndrome variables in rhesus monkeys.Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping studyInsulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's DiseaseAngiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer's Disease?Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's diseaseTriangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewedInsulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease.Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.The Angiotensin II Type 2 Receptor in Brain Functions: An Update.Inflammation and schizophrenia.Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.Body weight variability in midlife and risk for dementia in old ageAntidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairmentType 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathologyPPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.Thyroid function and the risk of Alzheimer disease: the Framingham Study.
P2860
Q26783344-66403BF1-57C7-4846-842E-5C2689A82A67Q26827439-21E6A86D-2B3A-4D2B-9626-E636D4AE647EQ27021700-EFA85ECF-D37D-4F3C-8524-0D6F215AA53BQ28259585-EEFBD69F-4C07-407D-8507-AA1757A97C9CQ28743487-5DF47460-B734-44D2-B377-D46406CC550AQ30478907-DFD7FD87-55BF-4C72-87A0-6F6614F4C5F4Q30484122-F05E0591-7336-4325-8988-0B23FE3218BFQ31143267-55618604-BFE8-4352-9EFB-9FCC990CD54CQ33543381-E47EE199-18C3-4BE0-824E-8A74F1D2FD88Q33629864-1E2344B5-632F-4858-8E30-FE997C14F577Q33674777-53A7A970-84E8-4D05-AF7C-8B53336A1D34Q33927061-6E405D1D-BECC-40A8-B23D-BDCC720D6E1AQ33944689-7388F19A-FE98-4AD8-8F4D-DEE62A2EBCA2Q34020000-FBB3D91A-E42A-4F71-9BDE-DA96EE405582Q34288447-07709722-8A17-426D-BDAF-C54E0F38F321Q34432135-572242F0-E607-4500-8153-673DA6410936Q34458197-DB129D1E-909D-4C0F-BF43-60B5C783E072Q34985810-8E5818E5-87B9-4117-85B4-9B9806496F59Q35050916-E7798067-4F66-487B-828D-3D028FBAD977Q35079816-31786BB8-0AEC-4894-A724-92CFA85B65B4Q35161815-573CA6DC-9BAD-4C7E-A77F-B01820F24DFCQ35610026-F9C72F57-621E-485D-9368-461D3A630520Q35690851-1438F91C-B554-4EBE-B48C-F3E185DD3354Q35912013-E5B58FC4-ECCB-4EDF-8E93-FFE90F077F8CQ35971305-DBB01C7F-EDE9-4D70-BEA6-964DF4C9C1DBQ35997824-F567A26D-E545-4441-B31B-53CE66137191Q35997884-D8349604-50D1-4290-B53B-0E86AA7D82EAQ36132651-6A2E2C37-22B2-4B35-8653-D0F1A241C86CQ36355644-38C983C0-D69F-4FED-A6E2-E57BF2A39F6BQ36520049-E8651735-CF2F-419E-BBAC-E09F23F237CDQ36870045-ACF233A5-BF4F-4B01-B465-423A497A646AQ37015867-192FEF6C-DE6A-4747-BECC-4DBF31F2518EQ37027509-2A0BACFE-889F-413C-A476-431A2585EB99Q37129434-AA61295D-EB60-4B05-B9E9-3AD3EF7F36B1Q37141691-1D8B5AA2-8012-4932-9854-028FD0E35FF0Q37158071-071CB777-84A0-4417-A123-A402D00B2228Q37164474-43CA74C9-1673-4510-BA69-FCFCDC72556CQ37178970-3C621438-3492-411A-9CB9-D49B9B44A6F4Q37215869-6FA2F952-F41B-45DB-81F8-FE591E284D64Q37223038-79A535D9-5AD9-4D44-9F80-E077631E4CC2
P2860
Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Insulin resistance syndrome an ...... and therapeutic implications.
@ast
Insulin resistance syndrome an ...... and therapeutic implications.
@en
type
label
Insulin resistance syndrome an ...... and therapeutic implications.
@ast
Insulin resistance syndrome an ...... and therapeutic implications.
@en
prefLabel
Insulin resistance syndrome an ...... and therapeutic implications.
@ast
Insulin resistance syndrome an ...... and therapeutic implications.
@en
P921
P1476
Insulin resistance syndrome an ...... and therapeutic implications.
@en
P2093
Suzanne Craft
P304
P356
10.1097/01.WAD.0000213866.86934.7E
P407
P577
2006-10-01T00:00:00Z